Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Retained Earnings: 2019-2025

Historic Retained Earnings for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to -$979.0 million.

  • Kymera Therapeutics' Retained Earnings fell 43.15% to -$979.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$979.0 million, marking a year-over-year decrease of 43.15%. This contributed to the annual value of -$754.6 million for FY2024, which is 42.18% down from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Retained Earnings is -$979.0 million, which was down 9.17% from -$896.8 million recorded in Q2 2025.
  • Kymera Therapeutics' Retained Earnings' 5-year high stood at -$141.8 million during Q1 2021, with a 5-year trough of -$979.0 million in Q3 2025.
  • For the 3-year period, Kymera Therapeutics' Retained Earnings averaged around -$661.0 million, with its median value being -$621.4 million (2024).
  • Data for Kymera Therapeutics' Retained Earnings shows a maximum YoY tumbled of 87.32% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Retained Earnings stood at -$229.0 million in 2021, then tumbled by 67.61% to -$383.8 million in 2022, then tumbled by 38.29% to -$530.8 million in 2023, then tumbled by 42.18% to -$754.6 million in 2024, then crashed by 43.15% to -$979.0 million in 2025.
  • Its last three reported values are -$979.0 million in Q3 2025, -$896.8 million for Q2 2025, and -$820.2 million during Q1 2025.